Compare DERM & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DERM | ARCT |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.9M | 193.8M |
| IPO Year | 2021 | 2019 |
| Metric | DERM | ARCT |
|---|---|---|
| Price | $7.11 | $7.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $12.67 | ★ $24.11 |
| AVG Volume (30 Days) | 338.9K | ★ 386.5K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.72 | 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | $61,858,000.00 | ★ $82,031,000.00 |
| Revenue This Year | $39.72 | N/A |
| Revenue Next Year | $63.24 | $12.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.20 | N/A |
| 52 Week Low | $4.31 | $5.85 |
| 52 Week High | $9.56 | $24.14 |
| Indicator | DERM | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 63.54 | 53.82 |
| Support Level | $7.00 | $6.79 |
| Resistance Level | $7.69 | $7.93 |
| Average True Range (ATR) | 0.44 | 0.42 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 86.21 | 48.75 |
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.